Encouragingly, the discovery of allosteric inhibitors of SHP2 featured with high potency, selection, and oral bioactivity offers an appealing and novel approach to suppress the growth of RAS-driven cancer cells, including lung cancer, pancreatic cancer, and leukemia cells (Garcia Fortanet et al., 2016; Dardaei et al., 2018; Fedele et al., 2018; Wang et al., 2020). Here, PTPN11 is linked to lung cancer.